Johnson & Johnson Just Backed an At-Home Depression Drug. The Release Says Psychedelics Stay in the Clinic
A biotech in Bedford, Massachusetts closed a 100 million dollar Series C on November 9. Johnson & Johnson led the round through its venture arm and took a board seat. The money advances a depression drug built to be taken at home.
That is the part worth reading twice. Johnson & Johnson sells Spravato, which by law can only be given in a certified setting under observation. It just funded the opposite model.
The in-clinic model is not going away this year. It is worth knowing what it costs to run. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 15 to 20 percent off malpractice and liability premiums, 40 percent or more off medical supplies, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The round | $100 million Series C, closed November 9, led by Johnson & Johnson and SV Health Investors |
| The drug | Zalsupindole, an oral compound inspired by 5-MeO-DMT, from Delix Therapeutics |
| The claim | Engineered without hallucinatory, dissociative, sedative or psychotomimetic effects |
| The setting | Delix calls it an at-home neuroplastogen and describes take-home medicines |
| The line about you | The release says traditional psychedelics will be limited to in-clinic care |
| The evidence | A Phase 1b reported about 50% mean MADRS reduction at Day 8, held to Day 36 |
| The gap | No placebo arm, participant count or named scales are given for those results |
What zalsupindole is
Delix Therapeutics describes zalsupindole as an orally bioavailable neuroplastogen inspired by 5-MeO-DMT, also called mebufotenin. The company says it is engineered to promote structural and functional neuroplasticity without hallucinatory, dissociative, sedative or other psychotomimetic effects.
Neuroplastogens are presented as a new class. The pitch is that you can keep what psychedelics do to synapses and discard the experience that comes with it.
Preclinical work cited in the release reports increased dendritic spine density in the prefrontal cortex. In animals, a single dose produced rapid and enduring antidepressant-like effects.
One investor put the thesis plainly. In his words, Delix is the first company to separate the neuroplastic benefits of psychedelics from their hallucinogenic effects.
The round itself was led by Johnson & Johnson Innovation and SV Health Investors’ Dementia Discovery Fund. RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital all returned. Adage Capital Management, Hamilton Square Partners, Vestal Point Capital and YK Bioventures came in new.
The dementia fund in that list is not decoration. The SV Health partner said the draw was the ability to increase synaptic density across preclinical models of Alzheimer’s and Parkinson’s disease. He called it something of a holy grail for the field.
The sentence that matters for a clinic
Most coverage will lead with the hundred million dollars. The more consequential line is a comparison Delix draws against the rest of the field.
The release contrasts its own approach with traditional psychedelics. Those, it says, will be limited to in-clinic care, later-line therapies and infrequent administration.
A subheading in the same release reads: advancing an at-home neuroplastogen into Phase II development. The company boilerplate describes fast-acting outpatient pharmacotherapies and take-home medicines.
So the positioning is explicit rather than implied. In-clinic administration is the thing this drug is designed to make unnecessary.
Whether that happens is a separate question from whether it is being funded. It is being funded.
What the Phase 1b actually reported
Delix reports a roughly 50 percent mean reduction in MADRS scores by Day 8. That followed one week of either daily or twice weekly dosing in adults with recurrent major depressive disorder. The improvement was maintained through Day 36, four weeks after the final dose.
The company also reports no serious adverse events to date, across more than 120 participants studied.
Those are real numbers and the durability figure is the interesting one. A month of maintained effect after the last dose is the claim a Phase 2 would need to reproduce.
What the release does not say
Three gaps are worth holding onto, because they decide how much weight the numbers carry.
The release gives no placebo arm for the Phase 1b, and no participant count for that trial specifically. An uncontrolled 50 percent improvement in a depression score is not the same finding as a controlled one.
That distinction is not academic in this field. We covered a psilocybin trial that reported 55 percent abstinence before 93 percent of patients guessed their group. It sits inside the wider blinding problem FDA faces across psychedelic trials.
The absence of hallucinatory effects is attributed to numerous clinician-administered scales, patient reporting scales and objective measures. None of those scales is named, and no published data is cited.
The Phase 2b in recurrent major depressive disorder is placebo-controlled and expected to start in the first half of 2027. That is the trial that will answer both questions.
Johnson & Johnson is now on both sides
Spravato is administered in a certified healthcare setting, with a prescriber on site and a monitoring period after dosing. That requirement is what created the esketamine clinic as a business.
The same company has now led a round in a compound whose stated advantage is needing none of that. A representative of its venture arm joined the Delix board.
The release describes no option, licensing term or right of first negotiation. Board representation is what it discloses, and that is all we are saying it discloses.
Read it as a hedge rather than a reversal. A company with a monitored product buying exposure to an unmonitored one is ordinary portfolio behavior. It is also a signal about where it sees the next decade.
What a clinic should take from this
Nothing changes operationally. Zalsupindole has not completed Phase 2 and will not be approved for years, if ever. Most compounds at this stage do not arrive.
What changes is the planning assumption. The argument that supervised administration is intrinsic to this class now has a well-funded opponent, arguing the opposite in writing.
We have tracked the same drift from other directions. Survey data showed unsupervised ketamine users rating it just as effective. Our own analysis found integration work moving into the home as clinical models get leaner.
The clinics that look durable in that world are the ones selling something a pill cannot replace. Monitoring, titration, management of complex cases, and the documented outcome record that proves it worked.
Patients comparing supervised options can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical or investment advice. Zalsupindole is investigational and is not approved for any indication. All figures are as reported by Delix Therapeutics.
